SEPN (Septerna, Inc.) Net Profit

SEPN (Septerna) - company brandmark

Septerna Inc (SEPN) develops innovative drugs for endocrinologists and oncologists using advanced GPCR receptor methodologies. This historical price chart on GURU.Markets, where the indicator stands at -0.03, links technological success to a team of top scientists attracted by high bonuses. The business relies on a proprietary AI system which, combined with massive R&D expenditures and FDA requirements, creates an insurmountable barrier to entry for new players.

SEPN (Septerna Inc) Net Profit history from 10/26/2024 to 10/29/2026

Analytical breakdowns and data insights for company Septerna (SEPN)

- price and consensus price forecast:
Stock Quotes Septerna Pharma|SEPN - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Septerna Pharma|SEPN - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Septerna|SEPN - Book Capitalization|Market Capitalization to Book Value septerna.com|SEPN - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Septerna Inc|SEPN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Septerna, Inc.|SEPN - Company Total Debt|Debts to Book Capitalization Septerna Pharma|SEPN - Company Long-Term Debt|Company Short-Term Indebtedness Septerna|Immediate Liquidity septerna.com
- net income and valuation multiples indicators:
SEPN - Company Net Income
Summary company analysis:Septerna Inc
Core merchandise of Septerna Corp

This indicator reflects the net financial result of the business, excluding the impact of one-time accounting adjustments to assess real efficiency. The metric captures daily cash flow, allowing for the identification of consolidation phases and the avoidance of false market signals. For Septerna Inc (SEPN), this calculation confirms the resilience of the molecule synthesis outsourcing model through vendor diversification. By analyzing the company's profit margins, an investor determines the stability of operational activities. The trend of this indicator serves as a filter before entering the asset.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN - Company Net Income|Net Financial Result Pharming Corp PHAR|NKTR: Net Profit|Company Net Income upstreambio.com (UPB)|Company Net Income Zenas Biopharma|Immunome Inc - Profit After Tax|Net Income GOSS (Gossamer Corp)|Profit After Payment of Taxes KALV|Net Profit PVLA (Pieris Pharmaceuticals)|savarapharma.com (SVRA) - Company Net Income|RIGL - Company Net Income|Final Profit ANAB (AnaptysBio Inc)|Astria Pharma (ATXS) - Company Net Income|Company Profit ENGN|RAPT (RAPT Therapeutics, Inc.) - Net Profit|Net Profit Aerovate|Net Income ACRS (Aclaris Therapeutics, Inc.)|KYTX (Kyverna Therapeutics Inc.) - Final Profit|Net Profit TLSA (Tiziana Life Sciences PLC)|Net Financial Result Cabaletta Bio Inc (CABA)|VTYX - Company Net Income|THTX (theratech.com) - Company Profit|AVTX: Net Profit|Net Income Eledon Pharmaceuticals Inc.|Company Net Income Agenus Inc|Climb Bio, Inc (CLYM) - Net Financial Result|Net Profit ZURA|ATYR - Company Net Income|Company Net Income Adagene Inc. ADAG|IMA (ImageneBio) - Profit After Tax|STTK - Company Net Income|EQ (Equillium, Inc.) - Company Profit|connectbiopharm.com (CNTB) - Company Net Income|Profit After Tax IMUX (Immunic)|ATRA (Atara Biotherapeutics, Inc.) - Net Profit|IFRX: Final Profit|Net Profit XFOR|Net Profit adicetbio.com (ACET)|Company Net Income Celularity CELU|Final Profit INMB|BRNS - Company Net Income|Kezar Life Sciences Inc. (KZR) - Net Income|SABS: Net Profit|Akari Therapeutics, Plc (AKTX) - Net Profit|Net Income ENLV|QTTB: Final Profit|Net Profit GOVX|Net Financial Result Edesa Biotech Inc|Company Net Income iBio Corp IBIO|CARM - Net Income|XTLB - Company Net Income|Bolt Biotherapeutics (BOLT) - Net Income|HCWB (hcwbiologics.com) - Net Income|Aptevo Therapeutics Inc. (APVO) - Net Profit|Company Net Income AIM ImmunoTech|Company Profit ADTX (Aditxt Corp)|Net Profit GRI|XRTX - Company Net Income|Company Net Income Vyome Holdings HIND|Net Financial Result Revelation Biosciences Inc (REVB)|Indaptus - Net Profit|Company Net Income BiondVax Pharmaceuticals|calcimedica.com (CALI) - Company Net Income|Profit After Tax AFMD (Affimed N.V.)|Net Income ALLK|HOOK (HOOKIPA) - Profit After Payment of Taxes|Net Profit IGMS|ITOS - Company Net Income|Company Net Income Ocean Biomedical, Inc. OCEA|Final Profit TCBP|THRD - Company Net Income